Spots Global Cancer Trial Database for Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Official Title: Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Study ID: NCT03798626
Study Description
Brief Summary: This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Of California LA UCLA Oncology Clinic, Los Angeles, California, United States
WA Uni School Of Med Siteman Cancer Center, Saint Louis, Missouri, United States
Sarah Cannon Research Institute Drug Ship - 4, Nashville, Tennessee, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Edegem, Antwerpen, Belgium
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Calgary, Alberta, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Santiago, , Chile
Novartis Investigative Site, Brno, Czech Republic, Czechia
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Ramat Gan, , Israel
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Rozzano, MI, Italy
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Osaka-city, Osaka, Japan
Novartis Investigative Site, Sunto Gun, Shizuoka, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Sevilla, Andalucia, Spain
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, Manchester, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
